Top

Drugs

Published in:

01-09-2000 | Adis New Drug Profile

Nateglinide

A Viewpoint by Willy J. Malaisse

Author: Willy J. Malaisse

Published in: Drugs | Issue 3/2000

Excerpt

Nateglinide is a non-sulphonylurea insulinotropic agent belonging to the family of so-called meglitinide analogues.[1] Conformational analysis,[2] characterisation of ionophoretic activity[3] and structures of calcium complexes,[4] detailed studies of uptake[5] and effects on nutrient catabolism,[6] cationic flux,[7] biosynthetic[8,9] and insulinotropic[10] actions in isolated rat pancreatic islet cells indicate that nateglinide owes its insulin-releasing properties to the direct inactivation of ATP-sensitive K⁺ channels in islet β-cells. …

Malaisse WJ. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Horm Metab Res 1995; 27: 263–6PubMedCrossRef

Lins L, Brasseur R, Malaisse WJ. Conformational analysis of non-sulfonylurea hypoglycaemic agents of the meglitinide family. Biochem Pharmacol 1995; 50(11): 1879–84PubMedCrossRef

Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ. Ionophoretic properties of the non-sulfonylurea hypoglycemic agents A4166 and KAD-1229. Res Comm Mol Pathol Pharmacol 1995; 88(3): 339–47

Lins L, Brasseur R, Malaisse WJ. Conformational analysis of the calcium complexes formed by meglitinide analogs. Res Comm Mol Pathol Pharmacol 1995; 90(1): 153–64

Malaisse-Lagae F, Malaisse WJ. Fate of ³H- and ¹⁴C-labelled A-4166 in pancreatic islets. Acta Diabetol 1996; 33: 298–300PubMedCrossRef

Malaisse WJ, Sener A. Effect of N-[(trans-4-isopropyl-cyclohexyl)-carbonyl]-D-phenylalanine on nutrient catabolism in rat pancreatic islets. Gen Pharmacol 1998; 31(3): 451–4PubMedCrossRef

Jijakli H, Ulusoy S, Malaisse WJ. Dynamics of the cationic and secretory responses to A-4166 in perfused pancreatic islets. Fundam Clin Pharmacol 1997; 11: 300–4PubMedCrossRef

Viñambres C, Garcia-Martinez JA, Villanueva-Peñacarrillo ML, et al. Preservation of nutrient-stimulated biosynthetic activity in pancreatic islets exposed to a meglitinide analogue. Postgrad Med J 1995; 71: 779–80

Jijakli H, Malaisse WJ. Preservation of protein biosynthesis in rat pancreatic islets exposed to A-4166. Med Sci Res 1997; 25: 813–4

10.

Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ. Insulinotropic action of meglitinide analogs: concentration-response relationship and nutrient dependency. Diabetes Res 1994; 27: 81–7PubMed

11.

Garcia-Martinez JA, Viñambres C, Villanueva-Peñacarrillo ML, et al. Comparison and synergism between the insulinotropic actions of succinic acid monomethyl ester and N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalani ne. Med Sci Res 1995; 23: 777–8

12.

Laghmich A, Ladrière L, Malaisse-Lagae F, et al. Long-term effects of glibenclamide and nateglinide upon pancreatic islet function in normal and diabetic rats. Pharmacol Res 1999; 40(6): 475–82PubMedCrossRef

Title: Nateglinide
A Viewpoint by Willy J. Malaisse
Author: Willy J. Malaisse
Publication date: 01-09-2000
Publisher: Springer International Publishing
Published in: Drugs / Issue 3/2000
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200060030-00009

At a glance: The STEP trials

Springer Medicine

Nateglinide

A Viewpoint by Willy J. Malaisse

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2000

Desirudin

Potential of Substance P Antagonists as Antiemetics

Nateglinide

Treatment of Chlamydia trachomatis Infections in Pregnant Women

Proficient and Cost-Effective Approaches for the Prevention and Treatment of Venous Thrombosis and Thromboembolism

Immune Tolerance Therapy for Haemophilia